Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus

NCT04598477 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT04598477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04598477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Follow-up Trial of ARGX-113-1904 to Evaluate the Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Pemphigus
Lead sponsor
argenx
Phase
Phase 3
Overall status
Terminated
Start date
July 15, 2021
Completion date
March 25, 2024
Enrollment
183 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

pemphigus foliaceus, pemphigus vulgaris